Renalytix inks partnership with the American Diabetes Association

Renalytix announced a joint programme with the American Diabetes Association (ADA) on Tuesday, to improve overall kidney health in patients with type-2 diabetes (T2D) in the United States.

The AIM-traded firm said the programme was designed to drive early detection and risk-informed care delivery to delay disease progression, reduce dialysis starts and improve overall health of chronic kidney disease (CKD) patients with diabetes nationally.

It said the number of patients with T2D in the US was expected to grow to almost 60 million by 2060, from 34 million individuals today.

Renalytix said the partnership would convene experts to advise and develop a “comprehensive, interprofessional risk-informed diabetes kidney care pathway and model” for optimal clinical treatment and risk reduction.

The ADA and the company would work to define a plan for the second phase of the programme, to scale and deploy the model through partnerships with multiple health systems nationally.

It said that effort would leverage milestones, key performance indicators, metrics and ongoing evaluation of the pathway's effectiveness in changing outcomes for people with diabetes living with or at-risk for CKD.

“This programme combines technology, hospital system population health engagement and leading clinical experts to drive optimised care management at the earliest possible stage of kidney disease where better outcomes and cost control can be maximised,” said Renalytix chief executive officer James McCullough.

“For individuals with diabetes and kidney disease, this is a powerful, comprehensive and bold model to engage this devastating disease beginning in primary care and close the gaps in front-line care.”

With the number of adults with diagnosed diabetes expected to reach 60 million in the US by 2060, Renalytix added that up to 40% of those were expected to develop chronic kidney disease.

It described CKD as a “silent disease”, killing more people each year than breast and prostate cancer.

“Early identification and risk-informed care are critical to better health outcomes,” said the ADA’s vice-president of healthcare improvement, Dr Nuha El Sayed.

“Our work together will support the care of people with diabetes through primary care providers.”

At 1039 GMT, shares in Renalytix were up 1.77% at 631p.